http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2024-08-21 16:41:282025-12-01 18:10:49Vandria closes Series A round at CHF28.3m
http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2024-03-28 16:44:392025-12-01 18:10:41Vandria: renewing mitochondria to treat CNS, muscle and other diseases
http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2024-02-13 16:47:072025-12-01 18:10:24Grant will advance VNA-318 for Parkinson’s, age-related diseases
http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2024-02-08 16:47:532025-12-01 18:10:16Vandria awarded grants to advance mitophagy drug candidates
http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2023-12-17 16:56:552025-12-01 18:09:58Vandria SA Raises CHF18m for Neurodegenerative Disease Treatment
http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2023-12-15 16:57:482025-12-01 18:09:49Vandria raises USD 20.6M and emerges from stealth
http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2023-12-14 16:58:412025-12-01 18:09:40Vandria emerges from stealth with $20.6m and clinic-ready lead candidate
